Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.41 |
| ▸ | CHRNG | P07510 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.41 |
| ▸ | CHRND | Q07001 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | PPID | Q08752 | 1/20 | 0.38 |
| ▸ | IL1RN | P18510 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870021 | 0.87 | CTSK (0.47) | CTSLCTSSCTSK | |
| SCHEMBL5870015 | 0.87 | CTSK (0.47) | CTSLCTSSCTSK | |
| SCHEMBL5870019 | 0.87 | CTSK (0.47) | CTSLCTSSCTSK | |
| SCHEMBL8440620 | 0.87 | FOLH1 (0.48) | HPGDRAB9ANPC1CYP1A2CYP2C19 | |
| SCHEMBL8437201 | 0.80 | IL1RN (0.50) | CYP1A2CYP2C19SMN1; SMN2FOLH1IL1RN | |
| SCHEMBL5869690 | 0.79 | ANPEP (0.50) | NLRP3CTSLCTSSCTSK | |
| SCHEMBL5869470 | 0.79 | ANPEP (0.50) | NLRP3CTSLCTSSCTSK | |
| SCHEMBL5869462 | 0.79 | ANPEP (0.50) | NLRP3CTSLCTSSCTSK | |
| SCHEMBL5869300 | 0.79 | ANPEP (0.50) | NLRP3CTSLCTSSCTSK | |
| SCHEMBL5869686 | 0.79 | ANPEP (0.50) | NLRP3CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | HPGD 156/4885RAB9A 2897/4885NPC1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.